Breaking News, Collaborations & Alliances

RecipharmCobra Biologics, KAHR Medical Continue KAHR-102 Pact

RCB to use maxXpress to help develop fusion protein for autoimmune indications

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

RecipharmCobra Biologics and KAHR Medical Ltd. have agreed to continue to advance candidate KAHR-102 for future preclinical and clinical testing using RecipharmCobra’s maxXpress service. KAHR develops novel drugs based on the Signal Converter Proteins (SCP) technology for the treatment of cancer and autoimmune diseases. The company has been collaborating with RecipharmCobra for four years. KAHR-102 is a fusion protein that is being investigated for use against autoimmune conditions such as psor...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters